# SHORT REPORT



# The constitutional gain-of-function variant p.Glu1099Lys in NSD2 is associated with a novel syndrome

Bernt Popp<sup>1,2</sup> Nelanie Brugger<sup>3</sup> Sibylle Poschmann<sup>4</sup> | Tobias Bartolomaeus<sup>1</sup> Maximilian Radtke<sup>1</sup> Hulia Hentschel<sup>1</sup> Nataliya Di Donato<sup>5</sup> Andreas Rump<sup>5</sup> Hatias Wagner<sup>3,7,8</sup> Ina Sorge<sup>9</sup> Johannes R Lemke<sup>1,10</sup> Thomas Meitinger<sup>3</sup> Rami Abou Jamra<sup>1</sup> Vincent Strehlow<sup>1</sup> H

<sup>1</sup>Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany

<sup>2</sup>Berlin Institute of Health at Charité, Universitätsmedizin Berlin, Center of Functional Genomics, Berlin, Germany

<sup>3</sup>Institute of Human Genetics, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany

<sup>4</sup>Division of Neuropediatrics, Clinic for Children and Adolescents Dritter Orden, Munich, Germany

<sup>5</sup>Institute for Clinical Genetics, University Hospital, TU Dresden, Dresden, Germany

<sup>6</sup>Division of Neuropaediatrics, Hospital for Children and Adolescents, University of Leipzig Medical Center, Leipzig, Germany

<sup>7</sup>Institute of Neurogenomics, Helmholtz Zentrum München, Neuherberg, Germany

<sup>8</sup>Division of Pediatric Neurology, Developmental Medicine and Social Pediatrics, Department of Pediatrics, Dr. von Hauner Children's Hospital, Munich University Hospital (Ludwig Maximilians University), Munich, Germany

<sup>9</sup>Department of Pediatric Radiology, University of Leipzig, Leipzig, Germany

<sup>10</sup>Center of Rare Diseases, University of Leipzig Medical Center, Leipzig, Germany

#### Correspondence

Bernt Popp, Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany.

Email: bernt.popp@medizin.uni-leipzig.de

Theresa Brunet, Institute of Human Genetics, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany. Email: theresa.brunet@mri.tum.de

Funding information Deutsche Forschungsgemeinschaft, Grant/Award Number: PO2366/2-1

#### Abstract

NSD2 dimethylates histone H3 at lysine 36 (H3K36me2) and is located in the Wolf-Hirschhorn syndrome (WHS) critical region. Recent descriptions have delineated loss-of-function (LoF) variants in *NSD2* with a distinct disorder. The oncogenic missense variant p.Glu1099Lys occurs somatically in leukemia and has a gain-of-function (GoF) effect. We describe two individuals carrying p.Glu1099Lys as heterozygous de novo germline variant identified by exome sequencing (ES) of blood DNA and subsequently confirmed in two ectodermal tissues. Clinically, these individuals are characterized by intellectual disability, coarse/ square facial gestalt, abnormalities of the hands, and organomegaly. Public cell lines with NSD2 GoF variants had increased K36me2, DNA promoter methylation, and dysregulated RNA expression. NSD2 GoF caused by p.Glu1099Lys is associated with a novel phenotype different from WHS and Rauch-Steindl syndrome (RAUST).

Bernt Popp, Melanie Brugger, Vincent Strehlow, and Theresa Brunet contributed equally to this work

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2022 The Authors. *Clinical Genetics* published by John Wiley & Sons Ltd.

INICAL ENETICS -- WILEY 227

#### KEYWORDS

gain-of-function, Glu1099Lys, neurodevelopmental disorder, NSD2, Rauch–Steindl syndrome, Wolf–Hirschhorn syndrome

# 1 | INTRODUCTION

Variants affecting genes encoding epigenetic proteins cause neurodevelopmental disorders (NDDs) and have been dubbed "Mendelian Disorders of the Epigenetic Machinery" (MDEM).<sup>1</sup> Clinically, these entities often comprise intellectual disability (ID) and growth abnormalities.

Epigenetic modifications of histone N-terminal lysine (K) residues affect DNA accessibility and transcriptional activity. Depending on the modified amino acid, they can serve as chromatin repressive (H3K27 methylation) or activating (H3K36 methylation) markers.

The nuclear receptor binding SET domain protein 2 (NSD2) catalyzes H3K36 methylation writing.<sup>2</sup> The previous name, Wolf-Hirschhorn syndrome (WHS, OMIM #194190) candidate 1 (*WHSC1*) indicates the gene's location in the critical deletion region. WHS was cytogenetically characterized before the micro-array era and refined as a contiguous gene deletion syndrome with two candidates (*NSD2* and *LETM1*) on 4p16.3 (OMIM #194190). The core clinical features of WHS include NDD, a typical facial dysmorphology described to resemble a "Greek warrior helmet" and intrauterine/ postnatal growth retardation.<sup>3,4</sup> A recent study described truncating and missense variants with loss of methylation activity in 18 individuals with mild developmental phenotypes that only partially overlap with WHS (Rauch-Steindl syndrome, RAUST, OMIM #619695).<sup>5</sup>

The other name for *NSD2*, "multiple myeloma SET domain containing protein" (MMSET), highlights the gene's involvement in hematologic malignancies.<sup>6</sup> The somatic t(4;14) translocation, present in 15–25% of multiple myeloma, fuses *NSD2* to the immunoglobulin heavy-chain (IGH) and causes overexpression. Sequencing studies identified a recurring somatic hotspot missense mutation in *NSD2* (E1099K; c.3295G > A, p.Glu1099Lys) in pediatric acute lymphoblastic leukemia (AML).<sup>7,8</sup> Both IGH-NSD2 and p.Glu1099Lys cause an expansion of H3K36me2 methylation.<sup>7,9</sup> Cryo-electron microscopy showed that p.Glu1099Lys destabilizes autoinhibition, increases substrate recognition and H3K36 methyltransferase activity.<sup>10,11</sup>

Here, we describe the NSD2 GoF variant p.Glu1099Lys as a constitutional, germline heterozygous de novo variant in two individuals with a syndromic NDD.

### 2 | MATERIALS AND METHODS

#### 2.1 | Ethics approval and consent

Leipzig University's Ethical Committee approved genetic testing for Ind\_1 (224/16-ek, 402/16-ek). For Ind\_2, the study was approved by

the Technical University of Munich (#5360/12S). Written consent from both parents to publish genetic, clinical, and image data was received and archived.

# 2.2 | Genetic analyses and comparison of phenotypes

NSD2 (NM\_001042424.2) variants in the index cases were identified by trio ES and confirmed by Sanger sequencing. For retrospective phenotyping and case reviews, we used an Excel questionnaire. Supplemental notes, Data S1, provide details and analyses of the variant spectrum, 3D structure, and omics data from cancer cell lines.

#### 3 | RESULTS

#### 3.1 | NSD2 variant spectrum


ES detected a heterozygous de novo missense variant in *NSD2* (NM\_001042424.3: c.3295G > A, p.Glu1099Lys; chr4[hg19]: g.1962801G > A) in both individuals. The constitutional status of the c.3295G > A, p.Glu1099Lys variant was confirmed in different tissues (Figure S1).

This variant had not previously been described as disease-causing when mutated in the germline and was listed once (1/251470 alleles) in gnomAD (possible mosaicism; Figure S2). As the phenotype of the individuals did not match the LoF descriptions (RAUST/WHS) the variant was classified as uncertain significance (VUS) according to the ACMG (American College of Medical Genetics and Genomics). Based on the clinical overlap between the two individuals, we upgraded to PS2\_strong, added PM1\_strong and PP2, allowing classification as "pathogenic."

*NSD2* LoF variants are dispersed throughout the protein (Figure S3A). Missense variants with a presumed LoF effect are located in functional domains but show no clustering in the tertiary structure, while the two missense variants with a proven GoF effect are close to each other and near lysine position 36 of H3 when the two proteins interact (Figure S3B).

#### 3.2 | Comparing NSD2 allelic disorders

Both individuals described here showed remarkable phenotypic overlap with complications in pregnancies and prenatal/postnatal periods as dominant features, prenatally detectable organomegaly, and postnatally evident dysmorphic features characterized by coarse/ square facies (Figure 1A–D,K) and large hands with tapering fingers (Figure 1E–J, Q-S; case reports in Supplementary notes). 228 WILEY GENETICS



**FIGURE 1** Clinical images. (A, B) frontal and (C, D) lateral facial images of Ind\_1. (E, F) dorsal and (G, H) palmar sides of the right hand of Ind\_1. (I, J) dorsal side of the feed of Ind\_1. Paired images are at age of 2 years 8 months and 8 years 3 months. (K) Full frontal body view of Ind\_1. (L) Hip X-ray of Ind\_2 showing almost horizontal acetabulum, widened proximal femoral metaphysis and prominent incisura ischiadica indicative of skeletal dysplasia. (M, N) abdominal MRI images of Ind\_2 showing hepatomegaly and nephromegaly. (O) Abdominal ultrasound of Ind\_2 displays kidney hypertrophy, diminished corticomedullary differentiation, irregular parenchyma, multiple small renal cysts, (P) hepatomegaly with rounded caudal margin in Ind\_2, and (Q, R) dorsal and palmar sides of the right hand of Ind\_2 showing short/ tapered fingers and hypoplastic fingernails. (S) Dorsal feet of Ind\_2 illustrating hypoplastic toenails. See Figure S5 for cranial MRI results of Ind\_1. [Colour figure can be viewed at wileyonlinelibrary.com]

NETICS WILEY 229

Our review found 26 individuals with (likely) pathogenic and presumed LoF variants carrying 23 variants, mostly truncating (n = 18, 78.3%) and a few missense (n = 5, 21.7%). We found varied facial dysmorphologies. GoF cases have coarse and square facial features, while LoF cases have a triangular face. LoF cases had a broad forehead with a high anterior hairline, while GoF cases had a low anterior hairline and a smaller forehead area. In both GoF cases, anteverted nares and an exaggerated cupid's bow were reported. A long philtrum was described in both GoF and 1/15 LoF cases.

In other phenotype categories, both GoF individuals and 0/12 LoF had short necks. Tapered fingers were described in both GoF cases but in only 1/18 LoF cases. Four other hand phenotypes were described in both GoF cases but were not phenotyped in the LoF cases (Table S2; compare Figure 1E-H,Q-R). Both GoF (nonspecific patent ductus arteriosus in Ind\_1) and 3/18 LoF cases had abnormal heart morphology. Abnormalities of the genitourinary system were described in both GoF cases but also in 7/23 (30.4%) of LoF cases and abnormal liver morphology was present in both GoF cases but only one LoF; assuming the other LoF cases were healthy, this is an important difference (Figure 1M-P). Both GoF cases had moderate, while most LoF cases had mild intellectual disability (73.7%; 14/19). Behavioral anomalies (47.4%: 9/19) and autistic behavior (30.4%: 7/23) were reported in LoF but not in the GoF cases. The two NSD2 GoF carriers had low-normal height (Ind\_1) or short stature (Ind\_2) and discordant head circumferences; macrocephaly in Ind 1 and microcephaly in Ind 2. The description of constitutional measurements is hindered by two factors: only two described individuals and postnatal intracerebral hemorrhage and growth hormone deficiency in Ind 2. Compare Tables S1 and S2.

Our analysis of cancer cell lines showed NSD2 GoF has higher mono- (me1) and dimethylation (me2) levels at H3 lysine 36 (K36). Differential DNA methylation and RNA expression analysis identified a large fraction of dysregulated genes that can be clustered into functional modules correlating with NSD2 function (Figure S4).

## 4 | DISCUSSION

A genetic disorder can be described by the affected gene, inheritance pattern, phenotypic description of the associated disease, and pathogenic variants' effect on protein function. This differentiation helps standardize genetic diagnostics for well-characterized rare disease cohorts and was advanced through the ClinGen group framework.<sup>12</sup>

NSD2 was a candidate in the WHS region, and LoF variants are associated with a milder NDD entity (Rauch-Steindl syndrome; RAUST). The NSD2 missense variant p.Glu1099Lys has been extensively studied because of its somatic recurrence in leukemia caused by a GoF effect. Here, we report two individuals with a syndromic NDD presentation harboring this GoF variant in the germline. When comparing the described individuals with NSD2 LoF individuals, some facial features seem inverted. While GoF carriers have a square face with a low anterior hairline and small forehead, LoF carriers have a triangular face with a high hairline and large forehead. The nasal bridge is wide and depressed in the two GoF individuals, but thin and elevated in the LoF cohort. With organomegaly and skeleton/hand/ foot abnormalities, NSD2 GoF appears syndromic compared to LoF. These phenotypic differences are expected given GoF and LoF's opposing cellular effects (compare Figure S4).

While the variant in Ind\_1 was identified by clinical ES about 6 years prior to this report, its highly suspected pathogenicity remained unclear until a second case was identified. This anecdotal diagnostic odyssey, combined with no other germline descriptions of this variant, argues for a rare disorder. No other GoF variant carriers have been identified despite posting the case to Clinvar, GeneMatcher, and genetic conferences. Still, ClinVar enabled the identification of the second individual and the description of this rare entity.

Due to the rarity of NSD2 GoF, it is hard to predict the clinical outcome and recommend treatment and surveillance. Both GoF individuals required intensive care postnatally. The course of Ind\_2 was complicated by brain hypoxia, which hampers assessing his development. On the other hand. Ind 1 shows a mild to moderate intellectual disability. which seems surprising given the strong histone methylation changes induced by the GoF variant (compare Figure S4). Similarly, while both individuals had organ abnormalities and organomegaly (kidneys, liver), laboratory findings were within normal ranges, indicating no signs of beginning organ failure. Due to the strong leukemia association of p.Glu1099Lvs, the most obvious concern in the two cases remains a possibly increased blood cancer risk, despite mostly unremarkable repeated blood counts (case report in Supplementary notes). An increased cancer risk has been described in other MDEM caused by variants in NSD1, DNMT3A and SETD2.13-15 A murine conditional knock-in model of p.Glu1099Lys in the B-cell lineage did not lead to the spontaneous leukemia development in immunocompetent mice.<sup>16</sup> Enrichment in AML relapses and functional studies showing induction of glucocorticoid resistance indicate that p.Glu1099Lys NSD2 GoF may cause clonal advantage and not be a primary driver.<sup>17</sup> We still recommend at least yearly blood counts, coupled with developmental assessment and abdominal organ ultrasound.

We describe a syndromic NDD entity associated with increased NSD2 activity and histone methylation disturbance. The specific phenotype, along with coarse facial features and hand abnormalities, may allow clinically supported diagnosis of a MDEM in individuals with other *NSD2* variants. GoF variation may cause a distinct *NSD2*-related disorder due to its clinical distinguishability from syndromes associated with NSD2 LoF and an antagonistic molecular consequence. As more individuals with NSD2 GoF variants are described, a distinct name could be chosen.

#### AUTHOR CONTRIBUTIONS

Bernt Popp, Melanie Brugger, Theresa Brunet, Rami Abou Jamra, and Vincent Strehlow conceived the study concept. Bernt Popp, Melanie Brugger, Matias Wagner, Tobias Bartolomaeus, Rami Abou Jamra, Theresa Brunet and Vincent Strehlow analyzed genetic data. Vincent Strehlow, Melanie Brugger and Theresa Brunet coordinated collection of clinical/genetic data. Melanie Brugger, Theresa Brunet and Bernt Popp reviewed literature data and standardized the HPO terms. <sup>230</sup> WILEY

Melanie Brugger, Sibylle Poschmann, Maximilian Radtke, Nataliya Di Donato, Janina Gburek-Augustat, Elisabeth Graf, Matias Wagner, Tobias Bartolomaeus, Julia Hentschel, Thomas Meitinger, Ina Sorge, Rami Abou Jamra, Theresa Brunet, and Vincent Strehlow provided clinical/genetic data and performed clinical assessments. Bernt Popp performed structural protein analysis, analyzed all data and created all main figures. Bernt Popp, Theresa Brunet, and Melanie Brugger created the Supplementary files. Bernt Popp, Melanie Brugger, Vincent Strehlow, and Theresa Brunet wrote and edited the manuscript. All authors reviewed, commented on, and agreed on the final draft manuscript.

#### ACKNOWLEDGMENTS

The authors thank all families for participating in this study. Bernt Popp was supported by the Deutsche Forschungsgemeinschaft (DFG) through grant PO2366/2-1. Open Access funding enabled and organized by Projekt DEAL.

#### CONFLICT OF INTEREST

All authors declare no competing interest for this study.

#### PEER REVIEW

The peer review history for this article is available at https://publons. com/publon/10.1111/cge.14241.

#### DATA AVAILABILITY STATEMENT

All data generated or analyzed can be found either at the publisher's website or has been uploaded to Zenodo at https://zenodo.org/ (File S2, S3, S4: DOI: https://doi.org/10.5281/ZENODO.6206868).

#### ORCID

Bernt Popp D https://orcid.org/0000-0002-3679-1081 Melanie Brugger 🕩 https://orcid.org/0000-0002-6920-8550 Tobias Bartolomaeus D https://orcid.org/0000-0002-5406-0776 Maximilian Radtke D https://orcid.org/0000-0003-0150-9709 Julia Hentschel 🝺 https://orcid.org/0000-0002-5706-1424 Nataliya Di Donato 🕑 https://orcid.org/0000-0001-9439-4677 Andreas Rump D https://orcid.org/0000-0001-7116-6364 Elisabeth Graf D https://orcid.org/0000-0002-1119-2285 Matias Wagner b https://orcid.org/0000-0002-4454-8823 Ina Sorge 厄 https://orcid.org/0000-0002-8992-5637 Johannes R Lemke ២ https://orcid.org/0000-0002-4435-6610 Thomas Meitinger D https://orcid.org/0000-0002-8838-8403 Rami Abou Jamra 🕩 https://orcid.org/0000-0002-1542-1399 Vincent Strehlow D https://orcid.org/0000-0003-1361-7766 Theresa Brunet 🕩 https://orcid.org/0000-0002-5183-780X

#### REFERENCES

- 1. Fahrner JA, Bjornsson HT. Mendelian disorders of the epigenetic machinery: postnatal malleability and therapeutic prospects. Hum Mol Genet. 2019;28:R254-R264.
- 2. Martinez-Garcia E, Popovic R, Min DJ, et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood. 2011;117:211-220.

- 3. Stec I, Wright TJ, van Ommen GJB, et al. WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a drosophila dysmorphy gene maps in the wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma. Hum Mol Genet. 1998;7:1071-1082.
- 4. Zollino M, Murdolo M, Marangi G, et al. On the nosology and pathogenesis of wolf-Hirschhorn syndrome: genotype-phenotype correlation analysis of 80 patients and literature review. Am J Med Genet C Semin Med Genet. 2008;148C:257-269.
- 5. Zanoni P, Steindl K, Sengupta D, et al. Loss-of-function and missense variants in NSD2 cause decreased methylation activity and are associated with a distinct developmental phenotype. Genet Med. 2021;23: 1474-1483.
- 6. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t (4:14) translocation in myeloma dysregulates both FGFR3and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood. 1998;92:3025-3034.
- 7. Oyer JA, Huang X, Zheng Y, et al. Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies. Leukemia. 2014:28:198-201.
- 8. Barretina J, Caponigro G, Stransky N, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603-607.
- 9. Kuo AJ, Cheung P, Chen K, et al. NSD2 links Dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell. 2011;44:609-620.
- 10. Li W, Tian W, Yuan G, et al. Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases. Nature. 2021;590:498-503.
- 11. Sato K, Kumar A, Hamada K, et al. Structural basis of the regulation of the normal and oncogenic methylation of nucleosomal histone H3 Lys36 by NSD2. Nat Commun. 2021;12:6605.
- 12. Strande NT, Riggs ER, Buchanan AH, et al. Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the clinical genome resource. Am J Hum Genet. 2017; 100:895-906.
- 13. Pappas J, Rabin R. SETD2 Neurodevelopmental Disorders. In: Adam MP et al., eds. GeneReviews<sup>®</sup>. University of Washington; 1993.
- 14. Hollink IHIM, van den Ouweland AMW, Beverloo HB, Arentsen-Peters STCJM, Zwaan CM, Wagner A. Acute myeloid leukaemia in a case with Tatton-Brown-Rahman syndrome: the peculiar DNMT3A R882 mutation. J Med Genet. 2017;54:805-808.
- 15. Kosaki R, Terashima H, Kubota M, Kosaki K. Acute myeloid leukemiaassociated DNMT3A p.Arg882His mutation in a patient with Tatton-Brown-Rahman overgrowth syndrome as a constitutional mutation. Am J Med Genet A. 2017;173:250-253.
- 16. Li J, Piper C, Dupere-Richer D, et al. NSD2-E1099K mutation leads to glucocorticoid-resistant B cell lymphocytic leukemia in mice. Blood. 2020;136:3-4.
- 17. Pierro J, Saliba J, Narang S, et al. The NSD2 p.E1099K mutation is enriched at relapse and confers drug resistance in a cell contextdependent manner in pediatric acute lymphoblastic leukemia. Mol Cancer Res MCR. 2020;18:1153-1165.

#### SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Popp B, Brugger M, Poschmann S, et al. The constitutional gain-of-function variant p.Glu1099Lys in NSD2 is associated with a novel syndrome. Clinical Genetics. 2023;103(2):226-230. doi:10.1111/cge.14241